Abstract
The recent coronavirus pandemic follows in its early stages an almost exponential expansion, with the number of cases as a function of time reasonably well fit by N (t) ∝ eαt, in many countries. We analyze the rate α in different countries, choosing as a starting point in each country the first day with 30 cases and fitting for the following 12 days, capturing thus the early exponential growth in a rather homogeneous way. We look for a link between the rate α and the average temperature T of each country, in the month of the epidemic growth. We analyze a base set of 42 countries, which developed the epidemic at an earlier stage, an intermediate set of 88 countries and an extended set of 125 countries, which developed the epidemic more recently. Fitting with a linear behavior α(T), we find increasing evidence in the three datasets for a decreasing growth rate as a function of T, at 99.66%C.L., 99.86%C.L. and 99.99995% C.L. (p-value 5 10−7, or 5σ detection) in the base, intermediate and extended dataset, respectively. The doubling time is expected to increase by 40% 50%, going from 5° C to 25° C. In the base set, going beyond a linear model, a peak at about (7.7 ± 3.6)°C seems to be present in the data, but such evidence disappears for the larger datasets. Moreover we have analyzed the possible existence of a bias: poor countries, typically − located in warm regions, might have less intense testing. By excluding countries below a given GDP per capita from the dataset, we find that this affects our conclusions only slightly and only for the extended dataset. The significance always remains high, with a p-value of about 10−3 10−4 or less. Our findings give hope that, for northern hemisphere countries, the growth rate should significantly decrease as a result of both warmer weather and lockdown policies. In general the propagation should be hopefully stopped by strong lockdown, testing and tracking policies, before the arrival of the next cold season.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are publicly available.
